13472
document
Alendronate daily , weekly in conventional tablets and weekly in enteric tablets : preliminary study on the effects in bone turnover markers and incidence of side effects . Bisphosphonates are now in the vanguard of osteoporosis treatment . Frequently , gastro-oesophageal symptoms are associated with these drugs . The objective of this study was to compare side effects and bone turnover markers in postmenopausal women who had received alendronate daily or weekly in tablets with or without enteric coating . We conducted a randomised , double-blind , 3-month trial . The trial involved 75 volunteers , aged 45-58 with moderate to severe osteopenia ( T-score lower than -2 SD ) assessed by quantitative ultrasound . Women were assigned randomly to receive : ( a ) alendronate 10mg/day : ( b ) alendronate 70 mg once a week : or ( c ) enteric alendronate 70 mg per week . We recorded side effects , C-telopeptide , osteocalcin and urine hydroxyproline at the start of the study and at 3 months . After 3 months , pyrosis ( heartburn ) was noted by seven women in group A ( 28 % ) , three in group B ( 12 % ) and two in group C ( 8 % ) ; nausea : by one woman in group B ; and headache by one patient in each group . C-telopeptide ( A : 40.7 % ; B : 34.1 % and C : 38.5 % ) ; hydroxyproline ( A : 31.1 % ; B : 25.3 % and C : 31.5 % ) and osteocalcin ( A : 27.0 % ; B : 25.4 % and C : 25.1 % ) decreased similarly in the three groups . Weekly intake of alendronate , whether conventional or enteric-coated ; is associated with less heartburn and nausea . Enteric alendronate has a similar action to the conventional tablets on biochemical markers .
13473
Intervention_Pharmacological
Alendronate
13474
Intervention_Pharmacological
Bisphosphonates
13475
Intervention_Pharmacological
alendronate
13476
Intervention_Pharmacological
alendronate 10mg/day
13477
Intervention_Pharmacological
alendronate 70 mg once a week :
13478
Intervention_Pharmacological
enteric alendronate 70 mg per week
13479
Intervention_Pharmacological
alendronate
13480
Intervention_Pharmacological
Enteric alendronate
13481
Outcome_Physical
bone turnover markers
13482
Outcome_Adverse-effects
incidence of side effects
13483
Outcome_Adverse-effects
side effects
13484
Outcome_Physical
C-telopeptide
13485
Outcome_Physical
osteocalcin
13486
Outcome_Physical
urine hydroxyproline
13487
Outcome_Physical
pyrosis ( heartburn )
13488
Outcome_Physical
nausea
13489
Outcome_Physical
headache
13490
Outcome_Physical
C-telopeptide
13491
Outcome_Physical
hydroxyproline
13492
Outcome_Physical
osteocalcin
13493
Outcome_Physical
heartburn and nausea
13494
Outcome_Physical
biochemical markers
13495
Participant_Condition
postmenopausal women who had received alendronate daily or weekly in tablets with or without enteric coating .
13496
Participant_Sample-size
75 volunteers
13497
Participant_Condition
,
13498
Participant_Age
aged 45-58
13499
Participant_Condition
with moderate to severe osteopenia ( T-score lower than -2 SD ) assessed by quantitative ultrasound